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Abstract: Congestion, as a symptom of upper respiratory tract diseases including seasonal and 
perennial allergic rhinitis, acute and chronic rhinosinusitis, and nasal polyposis, is principally 
caused by mucosal inflammation. Though effective pharmacotherapy options exist, no agent is 
universally efficacious; therapeutic decisions must account for individual patient preferences. 
Oral H1-antihistamines, though effective for the common symptoms of allergic rhinitis, have 
modest decongestant action, as do leukotriene receptor antagonists. Intranasal antihistamines 
appear to improve congestion better than oral forms. Topical decongestants reduce congestion 
associated with allergic rhinitis, but local adverse effects make them unsuitable for long-term 
use. Oral decongestants show some efficacy against congestion in allergic rhinitis and the 
common cold, and can be combined with oral antihistamines. Intranasal corticosteroids have 
broad anti-inflammatory activities, are the most potent long-term pharmacologic treatment of 
congestion associated with allergic rhinitis, and show some congestion relief in rhinosinusitis 
and nasal polyposis. Immunotherapy and surgery may be used in some cases refractory to 
pharmacotherapy. Steps in congestion management include (1) diagnosis of the cause(s), (2) 
patient education and monitoring, (3) avoidance of environmental triggers where possible, (4) 
pharmacotherapy, and (5) immunotherapy (for patients with allergic rhinitis) or surgery for 
patients whose condition is otherwise uncontrolled.
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Introduction
Congestion, which may be best described as a feeling of blockage, fullness, or restricted 
airflow, is a primary symptom of common upper respiratory tract disorders, includ-
ing allergic rhinitis, acute rhinosinusitis, chronic rhinosinusitis, and nasal polyposis. 
Congestion impacts negatively on patient quality of life by interfering with both sleep 
and daytime activities. In allergic rhinitis, it is the symptom patients find most bother-
some and would like most to prevent.1,2 Congestion may also exert secondary effects 
on the paranasal sinuses, ears, throat, voice, and chest that manifest as irritated throat, 
headaches, impairment in hearing, reduced ability to smell, worsening of asthma, 
problematic snoring, and disturbance of sleep.2
The principal underlying cause of nasal congestion in common upper airway 
disorders in adults is inflammation, which usually manifests as venous engorge-
ment, increased nasal secretions, and tissue swelling/edema that ultimately leads to 
impaired airflow and the sensation of nasal blockage. Consequently, development 
of pharmacologic therapies for congestion in these diseases has been guided by the 
need to target underlying pathophysiologic mechanisms including inflammation International Journal of General Medicine 2010:3 70
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(ie, anti-inflammatory activity of intranasal corticosteroids) 
and its manifestations such as venous engorgement (ie, vaso-
constrictive action of decongestants). It is important to note 
that the perception of congestion in chronic rhinosinusitis 
can also be caused by polyps extruding into the nasal airway, 
producing a physical obstruction in the nostrils.
The pervasiveness of allergic rhinitis3 and rhinosinusitis4,5 
has caused congestion to become a highly prevalent problem, 
even when less common causes are excluded. In addition, the 
upper airway respiratory diseases in which congestion is a 
common symptom (ie, allergic rhinitis, nonallergic/vasomo-
tor rhinitis, rhinosinusitis, nasal polyposis, and the common 
cold) are undertreated due to the lack of efficacy with some 
current therapies6–8 and safety concerns with others.6,9,10 Thus, 
there remains a large unmet clinical need for options for 
congestion, and further study and more effective therapies are 
necessary to improve treatment. This review covers treatment 
considerations for congestion associated with the common 
upper airway diseases described above. Also presented is a 
brief overview of treatments for some of the less common 
rhinopathies, as well as surgical options for congestion due 
to mechanical abnormalities and treatment-resistant chronic 
rhinosinusitis.
Treatment considerations
A stepwise approach is recommended for the management 
and treatment of nasal congestion. The 5 main principles 
are (1) diagnosis of the cause(s), (2) patient education and 
monitoring, (3) avoidance of environmental trigger fac-
tors where possible, (4) pharmacotherapy, and (5) allergen 
immunotherapy (only in patients with allergic rhinitis with 
documented sensitivity to specific allergens) or surgery for 
patients in whom the condition cannot be controlled with the 
previous measures.11
Patient education should involve the patient, family 
members, and any caregivers. Ideally it should begin at the 
time of diagnosis and continue throughout clinical care. 
Education of the patient should include an explanation of the 
condition and a definition of therapeutic goals. The physician 
should inquire about the patient’s concerns and preferences 
for various interventions and discuss potential side effects 
of treatment.12 Effective disease management should include 
a regular review of the treatment goals and monitoring of 
patient progress, including treatment adherence.
Once a diagnosis has been established, environmental 
triggers that may contribute to congestion should be avoided 
when possible. These triggers include allergens (eg, pol-
len, dust mites, animal dander, mold spores, cockroach 
droppings), irritants (eg, smoke, fumes, strong odors), and 
infectious agents.13 Environmental controls need to be tai-
lored to the individual patient’s exposures and sensitivities. 
Unfortunately, such controls are not always practical, effec-
tive, or indicated, and thus supplemental medical treatment 
is often required.1 For allergen exposure, environmental 
adjustments that have demonstrated efficacy include trigger 
avoidance, low indoor humidity (below 50%), allergen-proof 
pillows and mattress covers, minimizing carpeting, and mini-
mizing fur-bearing pet contact.13,14 Although a high-efficiency 
particulate air (HEPA) vacuum filter may reduce animal and 
dust mite allergen exposure, the evidence of its effectiveness 
in alleviating symptoms is not conclusive. Vacuuming of 
rugs is not effective in decreasing animal allergens, because 
it only eliminates superficial areas and does not clean the 
deeper levels of the rug.13 For irritants related to employment, 
appropriate control measures (eg, fume hoods, positive pres-
sure ventilation, air filtration, self-contained breathing units) 
should be implemented.
When developing a strategy for the pharmacologic 
treatment of nasal congestion, a physician should consider 
a number of factors, including the underlying etiology 
of the condition, likely pathophysiology and dominant 
symptom(s). The efficacy and safety of possible drug 
choices should be weighed against specific patient charac-
teristics such as comorbid airway disorders, age, appropri-
ateness of drug formulations, patient preference, prior and 
current therapy, and compliance history.12 In a 2005 survey 
of 783 allergy medication users conducted by the Gallup 
Organization, respondents were asked which drug charac-
teristics were most important to them. The most important 
properties to patients were: specifically targets individual 
symptoms (86%), fast onset of action (81%), few adverse 
events (79%), nonhabit forming (77%), and long duration 
of action (77%).15
Creating a collaborative partnership with patients and 
their families will help improve adherence. Clinical decisions 
should not only be made on the basis of the best available 
evidence but should also be consistent with patients’ expecta-
tions, preferences, goals, and capabilities. Patient adherence 
and compliance may also be affected by access to medica-
tions, including issues of product or formulation availability 
and cost. Important factors in improving patient adherence 
also include the selection of medications most appropriate to 
the patient’s clinical profile, avoidance of problems associated 
with past treatment, and appraisal of any new medications’ 
product attributes to determine if they align with the patient’s 
preferences. Patients should be instructed on the correct way International Journal of General Medicine 2010:3 71
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to use medication and encouraged to ask questions. Patient 
satisfaction with treatment should also be included in the 
process of follow-up and monitoring.
Medications that have been extensively evaluated in 
adequately designed clinical trials for the treatment of con-
gestion associated with various upper respiratory disorders 
include oral and intranasal antihistamines, leukotriene recep-
tor antagonists, oral and intranasal decongestants, and intra-
nasal corticosteroids.6,7,11 Other therapies such as intranasal 
cromones,6 topical lysine aspirin,16 topical anticholinergics,6 
systemic corticosteroids,11 capsaicin,17,18 menthol,19 and nasal 
douching6 have also been used for treatment of congestion, 
mostly in patients with rhinitis, but their ability to provide 
congestion relief has not been unequivocally demonstrated.
In patients with congestion due to allergic rhinitis, immu-
notherapy may be considered when previous options have 
proven insufficient to control symptoms. Immunotherapy 
has demonstrated efficacy against congestion and is the only 





H1-antihistamines exert their antiallergic effects by inhibiting 
the binding of histamine, an important mediator of allergic 
response, to the H1 histamine receptor.6 First-generation oral 
H1-antihistamines, such as chlorpheniramine, diphenhydr-
amine, and triprolidine, are associated with marked sedation, 
whereas the more recently introduced second-generation 
oral H1-antihistamines, including acrivastine, astemizole, 
azelastine, cetirizine, desloratadine, ebastine, fexofenadine, 
levocetirizine, loratadine, mizolastine, and terfenadine, have 
a more favorable benefit-to-risk profile (some of these agents 
are available only in Europe).6,10 Intranasal antihistamines 
include azelastine, levocabastine, and olopatadine.6,10,21
Although oral and intranasal H1-antihistamines have 
demonstrated efficacy against nasal congestion in patients 
with allergic rhinitis,10,22 the magnitude of benefit is relatively 
modest and less pronounced than that observed with decon-
gestants or intranasal steroids.10,23–28 Some improvement in 
congestion with oral and/or intranasal H1-antihistamines 
has also been reported in patients with nonallergic/vaso-
motor rhinitis,29,30 rhinosinusitis,31 and nasal polyposis,32,33 
whereas no effect on congestion was evident in studies of 
H1-antihistamines in patients with the common cold.34–36 
Key features of antihistamines include convenient oral or 
intranasal administration (in many cases, once daily), rapid 
onset of symptom relief, and good overall safety and toler-
ability profile.
Congestion efficacy in allergic rhinitis
Oral antihistamines
A recent meta-analysis of studies with oral H1-antihistamines in 
allergic rhinitis has demonstrated significant improvements in 
both patient-rated and physician-rated congestion.22 However, 
compared with their efficacy against other nasal symptoms 
associated with allergic rhinitis (eg, nasal itching, sneezing, 
rhinorrhea), oral (and intranasal) H1-antihistamines appear to 
be less effective for relief of congestion/obstruction.6,10 Nev-
ertheless, in clinical trials with various agents, both oral and 
intranasal antihistamines have demonstrated some congestion 
relief in patients with allergic rhinitis.
A placebo-controlled study of patients with seasonal 
allergic rhinitis reported that oral acrivastine 4 mg twice daily 
and 8 mg twice daily led to significant reductions in total 
symptom score, sneezing and runny nose, but the improve-
ments in congestion did not achieve statistical significance.37 
In a placebo-controlled trial with terfenadine 60 mg twice 
daily and astemizole 10 mg once daily in patients with sea-
sonal allergic rhinitis, astemizole showed superior relief of 
sneezing and runny nose versus both placebo and terfenadine, 
but the congestion scores with either antihistamine were 
not superior to placebo.38 Oral azelastine has demonstrated 
efficacy against nasal symptoms of perennial allergic rhinitis, 
but the improvement in congestion was only modest and did 
not achieve statistical significance at either the 1-mg twice 
daily or the 2-mg twice daily dose level.39 Studies with 
ebastine 10 mg and 20 mg in seasonal and perennial allergic 
rhinitis40,41 have also demonstrated some congestion relief 
versus placebo, but the improvement in congestion in patients 
with perennial allergic rhinitis failed to reach statistical sig-
nificance with either dose.40 Mizolastine therapy in patients 
with perennial allergic rhinitis also reduced congestion score 
after 4 weeks of treatment, but the improvement over placebo 
was not statistically significant.42
Some of the most extensively evaluated second-
generation oral H1-antihistamines in allergic rhinitis include 
loratadine, fexofenadine, cetirizine, desloratadine, and 
levocetirizine. In a study of adults with seasonal allergic 
rhinitis, loratadine was associated with greater improvements 
in nasal stuffiness score at day 4 and overall versus placebo, 
although the differences were not statistically significant for 
either comparison.24 A 4-week trial in adults with perennial 
allergic rhinitis showed that loratadine 10 mg once daily and International Journal of General Medicine 2010:3 72
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terfenadine 60 mg twice daily both significantly reduced 
nasal stuffiness compared with placebo.43 A pooled analysis 
of 3 studies in children with seasonal allergic rhinitis showed 
that fexofenadine 30 mg twice daily significantly reduced 
all nasal symptoms versus placebo, including congestion,44 
and a separate study in adults with seasonal allergic rhinitis 
reported that fexofenadine 120 mg once daily for 2 weeks 
significantly reduced nasal congestion score versus placebo.45 
In a small study of 31 patients with perennial allergic rhini-
tis, fexofenadine 120 mg once daily and 180 mg once daily 
both significantly decreased nasal congestion from baseline 
beginning 1 week after treatment and persisting until the 
end of 4 weeks of treatment, in contrast to the absence of 
significant reduction with placebo.46 However, fexofenadine 
is not approved for treatment of perennial allergic rhinitis 
in either the United States or Europe. A 2-week placebo-
controlled trial in adults with seasonal allergic rhinitis 
demonstrated significant improvements in congestion with 
both fexofenadine (120 mg once daily and 180 mg once 
daily) and cetirizine 10 mg once daily, but the magnitudes 
of improvement were less pronounced than for other nasal 
symptoms.47 In a 4-week study in adults with perennial 
allergic rhinitis, improvement in congestion with cetirizine 
10 mg once daily and 20 mg once daily was also greater 
than that observed with placebo, although the reductions in 
other nasal symptoms, most notably postnasal discharge and 
sneezing, were greater.48 In adults with intermittent allergic 
rhinitis, 2 weeks of therapy with desloratadine 5 mg once 
daily significantly reduced nasal congestion versus placebo at 
all time points evaluated.49 In patients with perennial allergic 
rhinitis, desloratadine 5 mg once daily significantly reduced 
all nasal symptoms with the exception of congestion over 
the 4-week treatment period.50 Treatment of adult patients 
with seasonal allergic rhinitis with 3 different dosing regi-
mens of levocetirizine (2.5 mg once daily, 5 mg once daily, 
and 10 mg once daily) for 2 weeks failed to significantly 
improve nasal congestion versus placebo despite superior 
efficacy on other nasal symptoms.51 In adults with persistent 
allergic rhinitis, therapy with levocetirizine 5 mg once daily 
was associated with a nonsignificant trend toward greater 
reduction in nasal congestion versus placebo at weeks 1 
or 4, and the reduction achieved statistical significance after 
6 months of treatment.52
Intranasal antihistamines
In general, clinical trials with intranasal antihistamines 
have demonstrated some efficacy against nasal congestion 
in allergic rhinitis compared with placebo, although no 
meta-analyses of studies with different agents have been 
published to date. Intranasal azelastine twice daily for 
2 weeks reduced nasal congestion in adults with seasonal 
allergic rhinitis significantly more than oral cetirizine 10 mg 
once daily. In an 8-week study in adults with perennial 
allergic rhinitis, intranasal azelastine failed to significantly 
reduce congestion versus placebo, in contrast to a significant 
reduction in congestion versus placebo reported with the 
intranasal steroid flunisolide.53 A 6-week trial in adults with 
seasonal allergic rhinitis showed minimal improvement in 
congestion-free days with intranasal levocabastine over pla-
cebo, whereas a significant improvement in congestion-free 
days versus placebo was observed with intranasal fluticasone 
propionate.54 A separate 4-week trial in adults with seasonal 
allergic rhinitis reported inferior all-day congestion relief 
with intranasal levocabastine compared with mometasone 
furoate nasal spray.55 Intranasal olopatadine therapy for 
2 weeks in adults with seasonal allergic rhinitis was associ-
ated with significant congestion relief compared with placebo 
in one study.56 But the reduction in congestion reported in a 
separate trial in adults with seasonal allergic rhinitis did not 
achieve statistical significance.57
Congestion efficacy in nonallergic/
vasomotor rhinitis
Only one study evaluated the effect of an oral antihistamine 
on congestion exclusively in patients with nonallergic rhinitis, 
although it is difficult to discern its effect because it was given 
in combination with an intranasal steroid. In that study, the addi-
tion of oral loratadine to intranasal flunisolide resulted in greater 
improvements in sneezing and rhinorrhea compared with 
flunisolide alone, but did not improve congestion.30 In a popula-
tion of patients with perennial allergic and nonallergic rhinitis, 
oral astemizole had a marginal effect on nasal congestion, in 
contrast to a significant improvement in congestion observed 
with intranasal steroid beclomethasone dipropionate.58
In a 2-week study in patients with vasomotor rhinitis, 
intranasal azelastine significantly reduced congestion at 
15 days, but the improvement reported at 8 days was not 
statistically significant.59 Some improvement of congestion 
with intranasal azelastine in patients with vasomotor rhinitis 
was also reported in another trial, although the effect was not 
consistently significant.29 A trial in patients with allergic and 
nonallergic disease, including symptoms of nasal obstruc-
tion, found no consistent benefit of intranasal levocabastine 
over placebo on nasal obstruction, and the intranasal steroid 
beclomethasone dipropionate was shown to be superior to 
levocabastine for nasal obstruction relief.60International Journal of General Medicine 2010:3 73
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Congestion efficacy in rhinosinusitis
Only one study reported the effect of an oral antihistamine 
on nasal congestion in patients with acute rhinosinusitis. This 
study demonstrated that, in patients with allergic rhinitis 
experiencing acute exacerbations of rhinosinusitis, loratadine 
significantly improved nasal obstruction compared with 
placebo after 28 days of treatment.31
Congestion efficacy in nasal polyposis
The only published study of oral antihistamine efficacy on 
congestion in nasal polyposis was conducted in patients with 
residual or recurrent nasal polyposis after ethmoidectomy 
who were treated with either cetirizine at twice the daily 
recommended (20 mg) dose or placebo for 3 months.32 The 
percentage of days with nasal obstruction score 1 (on a 
scale from 0 [no discomfort] to 3 [severe discomfort]) at 
weeks 4 and 8 in the cetirizine and placebo groups was 
similar, while patients treated with cetirizine had significantly 
more such days than placebo-treated patients at week 12.32 In 
the only trial of an intranasal antihistamine in patients with 
nasal polyps (and perennial allergic rhinitis), postsurgery 
treatment with azelastine nasal spray (0.14 mg to each nostril 
twice daily) had no consistent effect on nasal obstruction over 
a 25-week treatment period.33
Congestion efficacy in the common cold
In a trial in patients with the common cold, the reduction in 
congestion after 4 days of treatment with terfenadine 120 mg 
twice daily for 4 to 5 days was similar to that reported with 
placebo.34 A separate study in adults with the common cold 
reported that the combination of an oral antihistamine and 
decongestant (loratadine and pseudoephedrine) resulted in 
significant relief of patient-reported nasal stuffiness on days 
1 to 5 of treatment compared with placebo,61 but the effect 
attributable to the antihistamine could not be differentiated 
from that of the decongestant. In contrast, 2 other studies in 
patients with the common cold did not show a significant 
improvement in congestion with the combination of an 
antihistamine and a decongestant.62,63
Safety
The use of first-generation antihistamines (eg, diphenhydr-
amine, brompheniramine, chlorpheniramine) is associated 
with a number of adverse central nervous system (CNS) 
sedation effects, including somnolence and performance 
impairment.12 Other side effects of the older agents 
include anticholinergic effects, such as dryness of the 
mouth, urinary retention, and blurred vision.12 The newer 
H1-antihistamines, including cetirizine, desloratadine, 
fexofenadine, levocetirizine, and loratadine, are preferred to 
older agents because they have similar H1-receptor inverse 
agonist activity compared but are consistently less sedating, 
presumably due to reduced CNS penetration.64
In summary, clinical evidence suggests that antihista-
mines are, at best, a modestly effective therapy for congestion 
associated with allergic rhinitis. However, their deconges-
tant action is generally insufficient and inferior to that of 
intranasal steroids. Antihistamines may also provide some 
congestion relief in nonallergic upper respiratory diseases, 
although the supporting evidence is limited. From a safety 
standpoint, second-generation oral antihistamines are pre-
ferred over earlier agents because of an improved safety 
profile, although somnolence and performance impairment 
have also been reported with some of them.
Leukotriene receptor antagonists
Leukotrienes are contributing mediators of nasal allergic 
reactions, and their presence in the nose may lead to nasal 
obstruction.6 Therefore, a pharmacologic agent that inhibits 
the effects of leukotrienes might offer relief of symptom-
atic nasal congestion. Leukotriene receptor antagonists 
zafirlukast and montelukast have receptor affinities that are 
approximately 2 times greater than that of the natural ligand 
LTD4,6 which may enhance their clinical efficacy. Leukot-
riene receptor antagonists have demonstrated some efficacy 
against nasal congestion in allergic rhinitis and rhinosinusitis, 
although they appear to be inferior to intranasal steroids in 
this regard.
Congestion efficacy in allergic rhinitis
A meta-analysis of 6 placebo-controlled trials in patients with 
allergic rhinitis demonstrated that leukotriene receptor antago-
nists significantly reduce total nasal symptoms versus placebo, 
but the effect on congestion or other individual symptoms was 
not reported.65 While several small studies have evaluated the 
efficacy of zafirlukast66,67 and zileuton68 in patients with aller-
gic rhinitis, montelukast has been the only leukotriene receptor 
antagonist studied in large trials in these patients. A study in 
1302 patients with seasonal allergic rhinitis found that both 
montelukast and the antihistamine loratadine produced a 
modest decongestant effect after 2 weeks of treatment, with 
greater effects on other nasal symptoms.69 The combination 
of loratadine plus montelukast was found to be significantly 
more effective than either therapy alone for daytime nasal 
symptoms in patients with seasonal allergic rhinitis, although 
the effect on congestion was not significantly different International Journal of General Medicine 2010:3 74
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from montelukast alone.70 Moinuddin et al reported that the 
combination of loratadine and montelukast administered for 
2 weeks significantly improved peak nasal inspiratory flow in 
patients with seasonal allergic rhinitis, with the effect compa-
rable to treatment with fexofenadine and pseudoephedrine.71 
In a study of 1992 adults with perennial allergic rhinitis, 
6 weeks of treatment with montelukast achieved a signifi-
cantly greater improvement in all daytime nasal symptoms, 
including congestion, than placebo, although the study may 
have been overpowered (Figure 1).72
Several studies have documented that the congestion 
relief with leukotriene receptor antagonists is inferior to 
that achieved with intranasal steroids.8,73,74 In addition, the 
combination of leukotriene receptor antagonists and H1-anti-
histamines has also been shown to provide significantly less 
effective congestion relief than intranasal steroids.65
Congestion efficacy in nonallergic/
vasomotor rhinitis
There are no published reports on the efficacy of leukotriene 
receptor antagonists for relief of congestion associated with 
nonallergic/vasomotor rhinitis.
Congestion efficacy in rhinosinusitis  
and/or nasal polyposis
Antileukotrienes have not been adequately studied for 
the treatment of congestion associated with rhinosinusitis 
or nasal polyposis.7 In a small study of 40 patients who 
underwent surgery for nasal polyps, postoperative therapy 
with montelukast was significantly less effective than intrana-
sal beclomethasone for congestion relief over 12 months.75
Congestion efficacy in the common cold
No studies have been published on the efficacy of leukotriene 
receptor antagonists for relief of congestion associated with 
the common cold.
Congestion efficacy in aspirin 
triad disease
A small retrospective analysis reported the effect of antileu-
kotriene therapy (zarfirlukast or zileuton) for relief of conges-
tion in patients with aspirin triad disease who had persistent 
chronic rhinosinusitis despite previous paranasal sinus sur-
gery.76 Patient self-reports showed significant improvement in 
congestion and other major and minor symptoms, which was 
consistent with the findings of endoscopic nasal exams.76
Safety
Pediatric studies have demonstrated that montelukast is 
well-tolerated, with the majority of adverse events, includ-
ing headache, ear infection, nausea, abdominal pain, and 
pharyngitis, being mild.77 The incidence of these adverse 
events with montelukast does not appear to be higher than 
with placebo.78 No dose adjustment with montelukast is 
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Figure 1 Least squares mean change in the composite daytime nasal symptoms score and its components during a 6-week trial of montelukast versus placebo in patients with 
perennial allergic rhinitis. Baseline scores are shown above the bars. aP  0.001; bP  0.05. error bars represent Se. reproduced with permission from Patel P, Philip G, Yang w, 
et al randomized, double-blind, placebo-controlled study of montelukast for treating perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2005; 95(6):551–557.72 Copyright © 
2005 American College of Allergy, Asthma and Immunology.International Journal of General Medicine 2010:3 75
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Recently, the Food and Drug Administration (FDA) 
published reports of neuropsychiatric events associated with 
the use of montelukast and other antileukotrienes, including 
postmarket cases of agitation, aggression, anxiousness, dream 
abnormalities and hallucinations, depression, insomnia, 
suicidal thinking and behavior, and tremor. The FDA rec-
ommended remaining alert for such events and considering 
discontinuation of medication if these symptoms develop.80 
Isolated reports of Churg-Strauss syndrome, a rare systemic 
vasculitis associated with asthma, have been described in 
asthma patients treated with montelukast; a causal relation-
ship has not been established.81
In summary, the leukotriene receptor antagonist monte-
lukast has demonstrated some efficacy against nasal conges-
tion in allergic rhinitis. Its decongestant effects, both alone 
and in combination with an H1-antihistamine, are inferior 
to that observed with intranasal corticosteroids. The con-
gestion efficacy of other leukotriene receptor antagonists 
(eg, zafirlukast, zileuton, pranlukast) in allergic rhinitis and 
other upper respiratory disorders (ie, nonallergic/vasomotor 
rhinitis, rhinosinusitis, nasal polyposis, and the common cold) 
have not been adequately evaluated to date. The overall safety 
profile of leukotriene receptor antagonists is good.
Decongestants
Decongestants improve nasal ventilation and drainage 
through an α-adrenergic agonist vasoconstrictor mechanism. 
Topical decongestants include phenylephrine, pseudoephed-
rine, oxymetazoline, and xylometazoline. Common topical 
decongestant side effects include local irritation and rhinitis 
medicamentosa (drug-induced rhinitis) with extended use.82 
As a result, expert guidelines recommend that intranasal 
decongestant treatment be limited to brief use of less than 
10 days10,83 with switch to other therapies if symptoms persist 
after 5 days.84
Oral decongestants include phenylephrine and pseu-
doephedrine, with the latter being more effective. In some 
patients, their use can be associated with adverse systemic 
effects, including increased blood pressure, palpitations, 
appetite loss, and insomnia.13
Congestion efficacy in allergic rhinitis
Both oral and topical decongestants have proven effective 
for treating nasal congestion associated with allergic rhinitis. 
Topical decongestants are the most effective treatment for 
nasal congestion in subjects with allergic rhinitis, but their 
adverse effect profile make them suitable for short-term use 
only.6,10,11 Selner and colleagues used fiber-optic rhinoscopy 
to measure nasal patency in patients with nasal congestion 
due to allergic rhinitis. They reported significant symptomatic 
relief with both oral pseudoephedrine and topical oxymetazo-
line, which correlated with the total nasal airway area.85
A crossover study of asymptomatic patients with perennial 
allergic rhinitis due to house dust mite exposure compared 
the efficacy of the topical decongestant xylometazoline with 
the antihistamine/oral decongestant combination of cetirizine 
and pseudoephedrine. Following exposure to allergen and 
4 days of treatment, the 2 treatments appeared equally effec-
tive in alleviating nasal congestion.86 Although the topical 
decongestant had a more rapid onset of action, its effect was 
short-lived compared with the extended action of the oral 
drug combination.86 The response over 15 minutes to topical 
oxymetazoline was compared with the response over 28 days 
to the intranasal corticosteroid mometasone furoate in another 
crossover study in patients with perennial allergic rhinitis. 
The magnitude of the response was significantly greater with 
oxymetazoline than mometasone furoate for both subjective 
and objective outcomes of nasal obstruction, although there 
was high variability of response to oxymetazoline.87
A randomized, double-blind, 2-week study in patients 
with seasonal allergic rhinitis due to ragweed demonstrated 
that the oral decongestant pseudoephedrine was significantly 
more effective for relief of nasal congestion than the leu-
kotriene receptor antagonist montelukast.88 Importantly, the 
decongestant effect of oral pseudoephedrine in patients with 
seasonal allergic rhinitis is enhanced when administered in 
combination with newer H1-antihistamines, including ceti-
rizine,89 desloratadine,25,90 loratadine,24 and fexofenadine,26 
although the improvements in congestion favoring the 
combination therapy over oral decongestant alone are not 
consistently significant. Effective congestion relief with oral 
pseudoephedrine, alone or in combination with an antihista-
mine, has also been demonstrated in patients with perennial 
allergic rhinitis (Figure 2).23
Congestion efficacy  
in nonallergic/vasomotor rhinitis
No studies have been published that evaluated the effects of 
either oral or topical decongestants versus placebo in patients 
with nonallergic/vasomotor rhinitis.
Congestion efficacy in rhinosinusitis  
and/or nasal polyposis
While decongestants may provide relief from congestion in 
rhinosinusitis and/or nasal polyposis, no adequately designed 
studies have evaluated their efficacy in these conditions.7 International Journal of General Medicine 2010:3 76
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Only a few small studies of decongestants in rhinosinusitis 
have reported results, and they have failed to demonstrate 
consistent improvement in congestion. A study compar-
ing topical xylometazoline and oral pseudoephedrine in 
10 patients with chronic sinusitis found that the topical agent 
was more effective for nasal mucosa decongestion, although 
neither therapy had a significant effect on sinus congestion.91 
A study of 68 children with acute sinusitis treated with 
amoxicillin for 14 days found that symptoms improved as 
quickly in patients receiving a placebo as in those receiving 
an oral decongestant/antihistamine combination.92
Congestion efficacy in the common cold
A Cochrane database meta-analysis assessed the efficacy of 
topical decongestants in reducing nasal congestion in adults 
suffering from the common cold, demonstrating a modest but 
statistically significant 6% decrease in patient-reported symp-
toms after a single dose of intranasal decongestant compared 
with placebo.93 In addition, this meta-analysis also reported 
a statistically significant, 24% reduction in nasal airway 
resistance with the use of a decongestant.93 A small increase 
in the risk of insomnia with pseudoephedrine compared with 
placebo was one of the few adverse events.93 A double-blind, 
randomized, placebo-controlled trial in patients suffering 
from nasal congestion associated with the common cold 
reported that pseudoephedrine hydrochloride 60 mg 4 times 
daily for 3 days significantly reduced patient-reported con-
gestion compared with placebo on day 1, but not on day 3.94 
However, the mean decrease from baseline in congestion/
stuffiness over the study duration was significantly greater 
with pseudoephedrine than with placebo.94 A separate single-
dose trial reported that oxymetazoline reduced nasal airway 
resistance and symptoms of nasal blockage within 1 hour 
in adults with the common cold, and the effect persisted for 
up to 7 hours.95
Safety
The most common side effect of topical decongestants is 
rhinitis medicamentosa, and it limits the practical utility of 
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Figure 2 Nasal obstruction mean score versus treatment days. P  0.001 for COM vs CTZ; P = 0.004 for COM vs Per; P = 0.128 for CTZ vs Per. reproduced with permission 
from Bertrand B, Jamart J, Marchal JL, Arendt C. Cetirizine and pseudoephedrine retard alone and in combination in the treatment of perennial allergic rhinitis: a double-blind 
multicentre study. Rhinology. 1996;34(2):91–96.23 Copyright © 1996 International rhinologic Society.
Abbreviations: COM, combination of cetirizine and pseudoephedrine; CTZ, cetirizine; Per, pseudoephedrine.International Journal of General Medicine 2010:3 77
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oral decongestant, pseudoephedrine, is associated with an 
increased risk of insomnia, and the US Department of Justice 
has included pseudoephedrine in the Controlled Substances 
Act, limiting patients’ access.96
Despite their proven efficacy against nasal congestion 
associated with allergic rhinitis, the adverse event profile 
of topical and oral decongestants limits their usefulness in 
this disease. In addition, the evidence supporting the utility 
of decongestants for relief of congestion associated with 
nonallergic/vasomotor rhinitis, rhinosinusitis, or nasal pol-
yposis is very limited. However, these agents may be a more 
appropriate option for congestion relief related to the common 
cold, because of the shorter duration of treatment required.
Intranasal corticosteroids
Intranasal corticosteroids have potent and broad anti-inflam-
matory activities and have demonstrated congestion relief 
across the spectrum of upper respiratory disorders, includ-
ing seasonal and perennial allergic rhinitis, nasal polyposis, 
and both acute and chronic rhinosinusitis.6,7,10,11 Available 
intranasal corticosteroids include beclomethasone dipro-
pionate, budesonide, ciclesonide, flunisolide, fluticasone 
furoate, fluticasone propionate, mometasone furoate, and 
triamcinolone acetonide. Important features of an intranasal 
steroid include topical potency with low systemic bioavail-
ability, good acute and long-term efficacy, rapid onset of 
action, low risk of adverse events, and convenient dosing to 
promote adherence.
Congestion efficacy in allergic rhinitis
According to the Allergic Rhinitis and its Impact on Asthma 
(ARIA) guidelines, corticosteroids are currently the most 
effective anti-inflammatory medication available for the 
treatment of rhinitis.6 In comparative studies, intranasal 
corticosteroids have shown superior efficacy compared with 
other medications used to treat nasal congestion. A meta-
analysis of 14 controlled trials in patients with allergic rhinitis 
showed that intranasal steroids provide superior relief of 
nasal congestion/blockage compared with oral antihistamines 
(Figure 3A).27 Intranasal steroids also demonstrated greater 
effectiveness than intranasal H1-antihistamines in improving 
nasal blockage in a meta-analysis of 4 studies in patients with 
allergic rhinitis (Figure 3B).28 A separate meta-analysis of 4 
randomized controlled studies comparing leukotriene recep-
tor antagonists and intranasal steroids in patients with allergic 
rhinitis showed that steroids were more effective for improv-
ing composite nasal symptom scores (individual symptom 
scores, such as congestion, were not reported).97 In addition, 
several trials have demonstrated superior congestion relief 
with the intranasal steroid fluticasone propionate versus 
montelukast in patients with seasonal allergic rhinitis.8,73,74
Numerous studies have demonstrated that intranasal ste-
roids effectively relieve congestion due to seasonal allergic 
rhinitis. A study of 406 adults and children with seasonal 
allergic rhinitis found that once-daily intranasal budesonide 
treatment for 4 weeks significantly reduced nasal congestion.98 
Similarly, once-daily fluticasone propionate administered to 
adult patients with seasonal allergic rhinitis for 2 weeks also 
reduced clinician- and patient-rated scores for nasal obstruc-
tion.99 In a recent pooled analysis of 4 randomized, double-
blind, placebo-controlled studies comprising 982 adult and 
adolescent patients with seasonal allergic rhinitis, treatment 
with the intranasal steroid mometasone furoate was signifi-
cantly more effective than placebo in reducing nasal conges-
tion scores (Figure 4).100 Mometasone furoate was effective in 
relieving congestion across all severities of seasonal allergic 
rhinitis, with the magnitude of the benefit greatest in patients 
with the most severe congestion (Figure 4).100 A 2-week study 
of adults with seasonal allergic rhinitis reported that once-daily 
treatment with triamcinolone acetonide significantly reduced 
nasal symptoms, including congestion,101 and a 2-week study 
including adults and adolescents with seasonal allergic rhinitis 
reported that once-daily treatment with fluticasone furoate 
significantly reduced nasal symptoms, including congestion.102 
In a 2-week study of adults and adolescents with seasonal 
allergic rhinitis, once-daily treatment with ciclesonide signifi-
cantly reduced total nasal symptoms. However, the individual 
symptom scores were not reported.103
The congestion efficacy of intranasal steroids has been 
demonstrated across age groups. A study of 249 children 
with seasonal allergic rhinitis found that fluticasone pro-
pionate administered once daily for 4 weeks significantly 
improved nasal symptoms, including nasal obstruction upon 
awakening.104 In another trial conducted in 679 children with 
seasonal allergic rhinitis, once-daily mometasone furoate 
also significantly improved nasal congestion.105
In patients with predictable seasonal allergies, intranasal 
corticosteroids can be used as prophylactic therapy. Graft 
et al reported that an 8-week course of mometasone furoate 
200 µg once daily initiated before the start of ragweed season 
significantly delayed the onset of nasal symptoms, includ-
ing stuffiness/congestion in patients with seasonal allergic 
rhinitis.106
Intranasal steroids are also effective for treating nasal 
symptoms of perennial allergic rhinitis. A study of 550 adult 
and adolescent patients with moderate-to-severe perennial International Journal of General Medicine 2010:3 78
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Figure 3 A) Meta-analysis of intranasal corticosteroids versus oral H1-receptor antagonists for the treatment of nasal blockage in allergic rhinitis. Intranasal steroids included 
beclomethasone dipropionate, fluticasone propionate, triamcinolone acetonide, and budesonide. Oral antihistamines included dexchlorpheniramine, terfenadine, astemizole, 
loratadine, and cetirizine. Adapted with permission from British Medical Journal, weiner JM, Abramson MJ, Puy rM, volume 317, 1624–1629, Copyright © 1998 with permission 
from BMJ Publishing Group Ltd.27 B) Meta-analysis of intranasal corticosteroids versus topical H1-receptor antagonists for the treatment of nasal blockage in allergic rhinitis. 
Intranasal steroids included beclomethasone dipropionate, fluticasone propionate, and budesonide. Topical antihistamines included azelastine and levocabastine. Adapted with 
permission from Yáñez A, rodrigo GJ. Intranasal corticosteroids versus topical H1 receptor antagonists for the treatment of allergic rhinitis: a systematic review with meta-
analysis. Ann Allergy Asthma Immunol. 2002;89(5):479–484.28 Copyright © 2002 American College of Allergy, Asthma and Immunology.
allergic rhinitis found that once-daily treatment with either 
fluticasone propionate 200 µg or mometasone furoate 200 µg 
resulted in a significant reduction in patient-rated nasal conges-
tion compared with placebo.107 A 52-week study of once-daily 
treatment with ciclesonide in patients with perennial allergic 
rhinitis demonstrated significant relief of nasal congestion,108 
but no significant congestion benefit of ciclesonide versus 
placebo was observed in a 6-week study.109
Pediatric patients with perennial allergic rhinitis have also 
been effectively treated with intranasal steroids. Recently, 
fluticasone furoate 55 µg or 110 µg once daily has been 
reported to reduce total nasal symptom scores in pediatric International Journal of General Medicine 2010:3 79
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patients aged 2 to 11 years with perennial allergic rhinitis, 
although individual symptom scores were not reported.110 
In a previous study of 381 children aged 3 to 11 years with 
perennial allergic rhinitis, mometasone furoate 100 µg once 
daily was also significantly more effective than placebo in 
reducing patient-rated congestion.111
Congestion efficacy  
in nonallergic/vasomotor rhinitis
Intranasal corticosteroids have also been evaluated in the 
treatment of congestion associated with nonallergic rhinitis. 
Webb et al assessed the efficacy of fluticasone propionate 
treatment in 983 patients with perennial nonallergic rhinitis, 
with or without eosinophilia. They found that fluticasone pro-
pionate administered for 28 days was significantly better than 
placebo in improving total nasal symptoms (nasal obstruc-
tion, postnasal drip, and rhinorrhea; individual symptom 
scores were not reported).112 A 28-day study including 188 
patients with nonallergic rhinitis reported that patient-rated 
nasal congestion scores were significantly reduced during 
days 22 to 28 of treatment with fluticasone propionate.113
Congestion efficacy in rhinosinusitis
The anti-inflammatory effect of intranasal steroids has 
prompted study of these agents in acute and chronic 
rhinosinusitis. In light of these studies, European guidelines 
were published as the European Position Paper on Rhinosi-
nusitis and Nasal Polyps (EPOS) recommending the use of 
intranasal steroids for acute rhinosinusitis as monotherapy 
or as adjunctive therapy to systemic antibiotics with a high 
level of evidence (I), while noting that there is no evidence 
for intranasal steroids in the prophylaxis of recurrent acute 
rhinosinusitis.7 EPOS guidelines also note that there is some 
evidence for intranasal steroid efficacy in chronic rhinosinus-
itis without polyps, and that intranasal steroids have a high 
level of evidence (Ia) against nasal symptoms in chronic 
rhinosinusitis with polyps.7
Several studies have demonstrated the efficacy of intra-
nasal steroids as an adjunct to antibiotics in patients with 
acute rhinosinusitis.7,114–118 In 2 studies, patients with acute 
sinusitis were treated with amoxicillin clavulanate potassium 
(ACP) for 21 days and randomized to concurrently receive 
either adjunctive mometasone furoate or placebo.114,116 
Adjunctive intranasal mometasone furoate therapy was 
associated with significant improvements in congestion and 
total symptom scores compared with antibiotic treatment 
alone.114,116 Similar results were found with flunisolide as an 
adjunct to ACP in patients with acute sinusitis.115 The addi-
tion of intranasal flunisolide to oral ACP therapy significantly 




















































Figure 4 Percent change in congestion symptom score in a pooled analysis of 4 studies with mometasone furoate in seasonal allergic rhinitis. The magnitude of change was 
greatest in patients with the highest baseline congestion scores. Mean baseline congestion scores in the overall population were 2.24 in the mometasone furoate group and 
2.25 in the placebo group. In the 2.5 baseline congestion score group, the baseline scores were 2.83 (mometasone furoate) and 2.84 (placebo). In the 2.75 group, the 
baseline scores were 2.94 in both the mometasone furoate and placebo groups. aP  0.001 vs placebo. Adapted with permission from Berger we, Nayak AS, Staudinger Hw. 
Mometasone furoate improves congestion in patients with moderate-to-severe seasonal allergic rhinitis. Ann Pharmacother. 2005;39(12):1984–1989.100 Copyright © 2005 
Harvey whitney Books Co.International Journal of General Medicine 2010:3 80
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patients compared with antibiotic therapy alone (Figure 5).115 
Furthermore, nasal cytology revealed that neutrophils, eosin-
ophils, and basophils were all significantly decreased in the 
flunisolide-treated group.115 Another study evaluated the com-
bination of fluticasone propionate, cefuroxime, and a topical 
decongestant in patients with acute sinusitis. In this study, 
the addition of fluticasone propionate produced significantly 
higher rates of clinical success (defined as “cured” or “much 
improved”) than the combination of antibiotic/decongestant 
alone.117 The time to clinical success was also significantly 
shorter with the addition of fluticasone propionate.117
Corticosteroid/antibiotic combination therapy has also 
proved effective in pediatric patients. In 151 children with 
acute sinusitis, nasal discharge and cough were signifi-
cantly improved in subjects randomized to treatment with 
budesonide and amoxicillin compared with amoxicillin 
alone.118 Similarly, significantly higher recovery rates were 
reported in 52 children with acute maxillary sinusitis who 
were treated for 10 days with a combination of budesonide 
plus cefaclor compared with antibiotic therapy plus an oral 
decongestant.119
In addition to being effective when administered as an 
adjunct to antibiotics, intranasal steroids are also an effec-
tive therapy for congestion in acute rhinosinusitis when 
administered as monotherapy.120 In a study reported by 
Meltzer et al 981 adults and adolescents with acute rhinosi-
nusitis and symptoms persisting beyond 7 days, but without 
symptoms of severe disease, experienced significantly greater 
improvements in nasal congestion score during days 2 to 15 of 
the treatment period with mometasone furoate monotherapy 
than with amoxicillin alone or with placebo.120 A study by 
Lund and colleagues in patients with chronic rhinosinusitis 
demonstrated significantly greater improvement in conges-
tion with budesonide than with placebo.121
Congestion efficacy in nasal polyposis
EPOS 2007 guidelines recommend intranasal steroids for 
the treatment of nasal polyps with a level of evidence of Ia 
due to their well-documented efficacy in reducing polyp size 
and relieving symptoms associated with nasal polyposis, 
including nasal blockage. In 2 small-scale studies, fluticasone 
propionate nasal spray 200 µg twice daily or beclomethasone 
dipropionate nasal spray 200 µg twice daily significantly 
increased nasal inspiratory flow in patients with nasal polypo-
sis.122,123 Two large, randomized, placebo-controlled studies 
demonstrated that mometasone furoate nasal spray 200 µg 
once daily and particularly 200 µg twice daily significantly 
improved nasal congestion score at 1 month compared with 
baseline values, and this improvement persisted throughout 
the 4-month treatment period.124,125 In another study, intranasal 
fluticasone propionate nasal drops 400 µg once daily were also 
significantly more effective than placebo for reducing nasal 
blockage after 3 months of treatment in patients with bilateral 
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Figure 5 Mean change in turbinate swelling/obstruction score over 3 weeks in patients with acute rhinosinusitis treated with amoxicillin clavulanate potassium (ACP) 500 mg 
3 times daily (TID) and either flunisolide 100 µg 3 times daily or placebo 3 times daily. aP = 0.041 versus ACP 500 mg 3 times daily + placebo TID. reprinted from J Allergy Clin 
Immunol, Vol 92, Meltzer EO, Orgel HA, Backhaus JW, et al. Intranasal flunisolide spray as an adjunct to oral antibiotic therapy for sinusitis. Pages 812–823, Copyright © 1993, 
with permission from Mosby-Year Book, Inc.115International Journal of General Medicine 2010:3 81
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in the long-term for all patients with inflammatory polyps 
unless there is a compelling contraindication.127
Congestion efficacy in the common cold
The evidence for the efficacy of intranasal steroids against 
congestion associated with the common cold is limited, 
as only 2 such studies were reported in the literature. One 
double-blind, randomized, placebo-controlled study in 
young adults with the common cold reported that high-dose 
fluticasone propionate 200 mg 4 times daily for 6 days sig-
nificantly reduced nasal congestion on some but not all study 
days.128 Another trial found that intranasal beclomethasone 
dipropionate 400 µg/day failed to reduce symptoms caused 
by inflammation, such as congestion.129
Safety
Although the efficacy of intranasal corticosteroids is well 
established, these agents are frequently underused due to 
concerns about potential systemic adverse effects that are 
thought to be related to their systemic bioavailability. The 
systemic bioavailabilities of fluticasone propionate, flutica-
sone furoate, and mometasone furoate are low to undetect-
able (1%, 0.5%, and 0.1%, respectively) indicating a 
low potential for systemic side effects, especially compared 
with oral steroids and older intranasal agents within the drug 
class.130–132 The systemic bioavailability of other intranasal 
steroids ranges from roughly10% for budesonide133 to 44% 
for beclomethasone dipropionate.134 Triamcinolone aceton-
ide has a mean peak plasma concentration of approximately 
0.5 ng/mL at 1.5 hours postintranasal administration of a 
single 220 µg dose,135 and the absolute bioavailability of the 
inhaled formulation is 25%, which is predominantly due to 
the swallowed portion.136
Differences in the systemic bioavailability of intranasal 
steroids stem from a number of factors. Low circulating levels 
of some steroids might be due to minimal absorption across 
the nasal mucosa of these agents. Bioavailability may also 
vary with the proportion of drug absorbed by the gastrointes-
tinal tract. However, a significant portion of each intranasal 
steroid dose is swallowed, so that differences in the extent of 
first-pass hepatic inactivation seem to account for most of the 
diversity in systemic bioavailability across agents.137
Clinically significant inhibition of the hypothalamic-
pituitary-adrenal (HPA) axis is a potentially serious conse-
quence of systemic exposure to corticosteroids. Using cortisol 
concentrations as an indicator of HPA activity, mometasone 
furoate was found to have no effect on cortisol secretion in 
adults, even when the drug was administered at 20 times the 
recommended dose.138 Additionally, a study of children aged 
3 to 12 years who were treated with intranasal mometasone 
furoate for up to 14 days found no significant effect on mean 
plasma cortisol concentrations.139 Intranasal triamcinolone 
acetonide was also found to have no statistically significant 
effect on urine cortisol/creatine ratios in a study of 59 children 
with a mean age of 7.2 years.140 Although this same study 
reported small but detectable differences in plasma cortisol 
levels with fluticasone propionate,140 additional studies have 
demonstrated no detectable effects on the HPA axis following 
short-term intranasal triamcinolone acetonide or fluticasone 
propionate at their recommended dosages.141 Several studies 
with fluticasone furoate have reported small, variable changes 
in cortisol levels compared with placebo, which taken in 
whole cannot eliminate a potential effect of fluticasone 
furoate on adrenal function, especially in pediatric patients.132 
To minimize the potential risk of systemic side effects of any 
intranasal steroid, each patient’s dose should be titrated to the 
lowest dose that effectively controls symptoms.
Systemic corticosteroid exposure can cause a reduction 
in growth velocity in pediatric patients, even in the absence 
of detectable effects on HPA-axis function.142 A study of 
100 prepubescent children aged 6 to 9 years found that 
1 year of intranasal beclomethasone dipropionate treat-
ment resulted in detectable growth suppression.142 The 
mean change in standing height at study end point was 
5.0 cm and 5.9 cm in beclomethasone- and placebo-treated 
children, respectively.142 However, a 1-year growth study 
of 108 prepubescent children aged 3 to 9 years reported 
no statistically significant difference in growth velocity in 
patients receiving intranasal fluticasone propionate com-
pared with placebo, and no evidence of clinically relevant 
changes in HPA-axis function or bone mineral density.130 
Additionally, neither intranasal triamcinolone acetonide 
nor fluticasone propionate were found to have significant 
effects on short-term lower-leg growth velocity in a 2-week 
study.140 A long-term study noted no suppressive effect on 
growth over 1 year in 98 children aged 3 to 9 years treated 
with mometasone furoate.143
There are concerns that long-term corticosteroid use 
might result in atrophic changes in the nasal mucosa. How-
ever, no evidence of adverse changes in the nasal mucosa, 
including atrophy or epithelial thickness, were noted after 
12 months of daily treatment with mometasone furoate 
200 µg.144 Similarly, treatment with intranasal triamcinolone 
acetonide 220 µg daily for 6 months did not cause atrophy 
of the nasal mucosa or impairment of mucociliary function 
in patients with perennial allergic rhinitis.145International Journal of General Medicine 2010:3 82
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Despite the fact that intranasal steroids are the most 
effective therapy for symptoms associated with allergic 
rhinitis, they tend to be underused, especially in pediatric 
patients, due to concerns over potential side effects. However, 
the low to negligible systemic bioavailabilities of newer intra-
nasal steroids, in conjunction with the abundance of clinical 
trial evidence, suggest that these concerns may be somewhat 
exaggerated. Based on clinical trials that enrolled adult, ado-
lescent, and pediatric patients with allergic rhinitis, the inci-
dence of adverse events associated with the use of currently 
marketed intranasal corticosteroids was generally low and 
similar to placebo.130–135 Numerous studies have demonstrated 
that intranasal corticosteroids offer effective relief of nasal 
congestion in seasonal allergic rhinitis and perennial allergic 
rhinitis, and can even be used to prevent nasal congestion 
associated with seasonal allergic rhinitis when given before 
the start of allergen season. Intranasal corticosteroids have 
also provided relief of congestion associated with nonallergic 
rhinitis and have demonstrated superior efficacy with respect 
to congestion relief in patients with acute rhinosinusitis, both 
when used as an adjunct to antibiotics and as monotherapy. 
In addition, intranasal corticosteroids provide effective 
congestion relief in patients with nasal polyposis. Further 
evaluation of their ability to relieve congestion associated 
with the common cold is needed.
Although intranasal steroids are the most effective agents 
for the relief of congestion associated with allergic rhinitis, 
there is room for improvement in this treatment class. Mean 
nasal congestion scores are not reduced to normal levels in 
clinical trials with these agents, and congestion is not effec-
tively reduced in all patients. Systemic availability is very 
low for some intranasal steroids, but for others it can be quite 
substantial, leading to safety concerns.
Other pharmacotherapies
Cromolyn prevents inflammation through its inhibition 
of mast cells, macrophages, eosinophils, monocytes, and 
platelets.146 While cromolyn is an effective treatment for 
symptoms of sneezing, rhinorrhea, and nasal itching in 
patients with allergic rhinitis, it is less efficacious against 
nasal obstruction.6 In addition, its decongestant effect is 
inferior to that of intranasal steroids, such as mometasone 
furoate.55 Cromolyn has a good safety record and is avail-
able without prescription.147 Intranasal cromolyn sodium 
has not been proven effective for treatment of congestion 
associated with other upper respiratory diseases, including 
nonallergic/vasomotor rhinitis and the common cold, as well 
as rhinosinusitis and/or nasal polyposis.7
A topical form of aspirin, lysine-aspirin, has been used 
in the treatment of nasal polyposis. Objective assessments 
showed that lysine-aspirin had significant clinical benefit in 
improving nasal blockage and reducing polyp size when used 
in addition to topical corticosteroids,148 possibly related to a 
reduction in leukotriene receptors.16
Because parasympathetic nervous system activation 
induces watery secretion and vasodilatation, it has been 
postulated that topical anticholinergics may provide efficacy 
against nasal congestion. However, randomized, controlled 
trials have shown that the anticholinergic ipratropium bro-
mide provides no relief of nasal obstruction in patients with 
perennial allergic and nonallergic/vasomotor rhinitis.6,149,150 
In addition, the systemic bioavailability of intranasal ipratro-
pium (7% to 18%)151 is much higher than that of the second-
generation intranasal corticosteroids, including fluticasone 
propionate, mometasone furoate and fluticasone furoate, 
and thus increases the potential for systemic side effects. 
As patients with perennial rhinitis typically suffer from a 
variety of symptoms, including nasal congestion, itching, and 
sneezing, other therapeutic agents are preferable as first-line 
treatment in the majority of patients with allergic rhinitis.6
Oral methylprednisolone has been shown to provide sig-
nificant relief of nasal congestion in patients with moderate-
to-severe seasonal allergic rhinitis symptoms compared with 
placebo over a 1-week treatment period.152 In addition, it has 
demonstrated the ability to relieve a nonvascular component 
of allergic congestion that is unaffected by decongestant 
therapy.153 However, systemic steroids should not be used as 
first-line treatment for allergic rhinitis, but only as a therapy 
of last resort when other therapeutic options have been 
exhausted.6 Oral corticosteroids have also been evaluated 
in acute rhinosinusitis, but there is little evidence to support 
their use for purposes other than pain relief.84 Although no 
data is available for their efficacy in chronic rhinosinusitis 
without nasal polyps, recent studies show that short courses 
of oral corticosteroids reduce polyps and improve congestion 
in most patients with chronic rhinosinusitis and polyps.7,154 
From a safety perspective, for nasal congestion, systemic 
corticosteroids should be limited to short-term use due 
to their side-effect profile,6 which effectively reduces the 
clinical usefulness of these agents. In addition, systemic 
steroids should be limited as much as possible in children, 
and avoided in pregnant women and in patients with a known 
contraindication.6
The C-fiber stimulant capsaicin has also been tested as a 
therapeutic option for relief of nasal congestion. It has been 
suggested that the therapeutic effect of capsaicin could be International Journal of General Medicine 2010:3 83
Treating upper respiratory disease congestion Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
mediated by C-fiber desensitization through continuous 
stimulation. A study in adult patients with severe, chronic 
nonallergic rhinitis receiving intranasal capsaicin under local 
anesthesia once weekly for 5 weeks reported a significant 
improvement in nasal obstruction throughout a 6-month 
follow-up period.155 However, in a separate randomized, dou-
ble-blind, placebo-controlled trial in adults with nonallergic 
rhinitis, capsaicin provided no relief of nasal congestion.17
Menthol is an alcohol that has been widely used for 
the relief of nasal symptoms in various upper respiratory 
diseases. A double-blind, randomized trial in patients with 
nasal obstruction due to the common cold found that oral 
administration of a lozenge containing 11 mg of menthol 
increased patient’s sensation of airflow 10 minutes after 
lozenge administration, but this effect did not persist.156 
Additionally, menthol did not have an impact on nasal resis-
tance to airflow.156
There is mounting evidence that nasal irrigation with 
saline is beneficial in treating nasal symptoms in acute and 
chronic rhinosinusitis, when used as a sole modality or as 
adjunctive therapy, although such treatment is less effective 
than intranasal corticosteroids.7,83,157,158 Various mechanisms, 
including improved mucous clearance, may account for the 
improvement.157 Recent controlled trials in both children and 
adults with rhinosinusitis and allergy show that saline wash-
outs significantly relieved nasal congestion and other symp-
toms as well as improved sleep and quality of life.159,160 
Immunotherapy
Immunotherapy for allergic rhinitis involves periodic expo-
sure, usually weekly by subcutaneous injection (SCIT) or 
daily by sublingual tablet or drops (SLIT), to incrementally 
larger doses of allergen(s).20,161–163 A maintenance dose is 
usually continued long-term with SCIT at intervals of 2 to 
6 weeks,20 and allergen(s) may be modified with adjuvant 
agents to enhance allergen immunogenicity.20,161 Immuno-
therapy offers a number of advantages over conventional 
pharmacotherapy, as it appears to offer some benefit in cases 
of severe allergic rhinitis,20 and its clinical efficacy can be 
maintained for years after treatment discontinuation.161 In 
addition, immunotherapy may reduce the risk of developing 
asthma in patients with allergic rhinitis161 and may prevent 
new sensitizations.161 A study by Durham et al evaluated 
the long-term efficacy of grass pollen SCIT in patients who 
responded favorably to treatment for up to 4 years. After dis-
continuation of therapy for 3 years, symptom scores and res-
cue medication scores remained at low levels and were similar 
to those of patients who continued immunotherapy.164
SCIT has been shown to effectively reduce nasal conges-
tion in allergic patients. A double-blind, placebo-controlled 
trial in patients allergic to Parietaria found that treatment with 
an alum adsorbed partially purified Parietaria extract (Alpare 
parietaria) for 2 years significantly decreased nasal blockage 
in the actively treated immunotherapy group compared with 
placebo.165 Similarly, a randomized, double-blind, placebo-
controlled study in adults with a history of severe grass pollen 
allergy not controlled by standard antiallergic drugs found 
that administration of a depot grass pollen extract (timothy 
grass, Phleum pratense) significantly reduced blocked nose 
during the pollen season compared with placebo.166
Similar to SCIT, SLIT has also demonstrated conges-
tion relief in subjects with allergic rhinitis. An older study 
investigating the utility of oral ragweed immunotherapy 
reported that nasal symptom scores during the natural 
allergen season were numerically but not statistically lower 
in the SLIT group versus the placebo group.167 However, a 
more recent double-blind, placebo-controlled study of 634 
patients with allergies to timothy grass pollen demonstrated 
that sublingual timothy grass tablet significantly improved all 
ocular and nasal symptom scores, including blocked nose.168 
Timothy grass tablet SLIT has also proven effective when 
initiated prior to the allergy season and continued throughout 
the pollen season.162,169 A recent multinational, randomized, 
double-blind, placebo-controlled study performed in 628 
grass pollen–allergic patients reported that treatment with a 
SLIT tablet containing a mixture of equal proportions of 5 
grass pollens (including orchard grass, meadow grass, peren-
nial ryegrass, sweet vernal, and timothy) initiated 4 months 
before the pollen season and continued throughout the season 
significantly reduced nasal congestion scores compared with 
placebo.170 In addition to the efficacy of grass tablet SLIT 
on nasal congestion in patients with seasonal grass aller-
gies, house dust mite SLIT has also been shown to reduce 
nasal blockage in patients with perennial allergic rhinitis. 
Patients with perennial rhinitis related to house dust mite 
sensitization randomized to receive house dust mite SLIT 
for 2 years reported significant improvements in congestion 
scores versus placebo after 1 year, and these improvements 
persisted at the end of the second year.171
Potentially fatal anaphylaxis is the most serious clinical 
concern surrounding the use of allergen immunotherapy.161 
Cases of fatal anaphylactic reactions have been reported with 
the use of SCIT,20 but not with SLIT tablets. The proportion 
of patients receiving SCIT who suffer systemic reactions is 
estimated at 5% to 10%.20 With SLIT tablets, the most com-
mon adverse events include swelling and itching of the ears, International Journal of General Medicine 2010:3 84
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mouth, and throat, which are typically mild in severity and 
resolve spontaneously after a short period of time.164,168,169 
Because of the potential for fatal or near-fatal anaphylactic 
reaction to immunotherapy, SCIT is always administered in 
a physician’s office with ready availability of epinephrine 
for rescue, whereas SLIT tablets have been designated to 
be given under a physician’s supervision on the first 1 or 2 
occasions, but can be taken by the patient on their own at 
home thereafter.
Immunotherapy is specifically designed to treat both 
seasonal and perennial allergic rhinitis and has demonstrated 
efficacy against nasal congestion in both conditions. How-
ever, concerns related to SCIT, including potential for ana-
phylaxis, uncertainty concerning the strength of administered 
extracts, the discomfort and expense of frequent injections 
with SCIT, and patient inconvenience, have limited its adop-
tion in clinical practice.20 Despite these problems, immuno-
therapy may be indicated for patients with allergic rhinitis 
if the relief achieved with pharmacotherapy is inadequate 
or to reduce disease progression, as immunotherapy is the 
only intervention that alters the natural history of allergic 
disease.20 In addition, the recent introduction of fixed-dose 
tablet SLIT may offer an effective and potentially safer and 
more convenient alternative to SCIT.
Surgical treatments
Surgical treatment for nasal congestion should be reserved for 
severe or persistent cases of nasal obstruction. The relevant 
anatomical sites for surgical intervention include the nasal 
septum, nasal valve, inferior and middle turbinates, and naso-
pharynx. The nasal septum can interfere with nasal airflow 
when it is skewed from its midline position, either unilaterally 
or bilaterally. Deformity of the septum can be due to curva-
tures of anterior cartilages, spurring or displacement of bony 
nasal supports, or both. Among available surgical procedures 
for improving nasal obstruction caused by septal deformity 
are septoplasty and submucous resection of the septum.
The long-term benefits of septal surgery have been 
described in a number of studies.172–174 A trial in patients 
diagnosed with a septal deviation requiring surgery to elimi-
nate obstruction reported a statistically significant increase in 
volume as measured by acoustic rhinometry and a decrease 
in symptomatic congestion.172 In addition, a 2- to 3-year 
follow-up study of patients who underwent septoplasty found 
significant improvement in nasal breathing and congestion.173 
A retrospective study found a high degree of patient satis-
faction in those who had undergone septoplasty for nasal 
obstruction 3 months earlier.174
Anatomical regions of the nasal airway that dynamically 
affect nasal breathing include the external nasal valve and the 
internal nasal valve. The nasal valve is the narrowest portion 
of the nasal airway and accounts for 50% of normal nasal 
resistance. Collapse of the nasal valve with inspiration (alar 
collapse) is a common cause of nasal obstruction. Surgical 
repair of this area can improve nasal airflow and decrease 
obstruction/ congestion.175
The nasal turbinates are paired bilateral structures arising 
from the ethmoid and maxillary bones. Turbinate hypertrophy 
can include bony structures with or without mucosal swelling, 
which can be differentiated by acoustic rhinometry pre- and 
postnasal decongestion. Surgery should be reserved for cor-
recting bony structural problems or mucosal swelling that has 
failed to remit with maximal medical therapy, including use 
of oral corticosteroids. Various procedures have been used 
to reduce turbinate bulk, including turbinectomy (resection 
and surgical reduction of the turbinates), submucous resection 
of turbinate bone, submucosal diathermy, laser ablation, and 
radiofrequency ablation.176,177
A number of positive outcomes have been reported in 
patients who have undergone turbinate surgery. The proce-
dure has been reported to improve nasal airflow,177,178 reduce 
symptoms of nasal obstruction,177,179,180 and increase nasal 
cavity volume.180 Although turbinate surgery is effective in 
properly selected patients, the procedure is subject to a number 
of drawbacks, including persistent nasal problems as the result 
of less aggressive procedures. On the other hand, complica-
tions of overly aggressive or complete turbinectomies include 
the risk of atrophic rhinitis and “open nose.”181 In addition, 
postoperative development of dry rhinitis characterized by the 
accumulation of stagnant secretions resulting from excessive 
removal of the inferior turbinate has also been reported.181
Adenoid hypertrophy can affect nasal airflow by causing 
posterior nasal/nasopharyngeal obstruction. In many patients, 
especially children, adenoid hypertrophy is associated with 
hypertrophy of the inferior turbinates,182 suggesting that 
adenoidectomy might improve symptoms of nasal obstruc-
tion in these patients. While adenoidectomy has been shown 
to decrease nasal congestion and improve nasal airflow in 
children,182,183 its role in adults is limited.
A major symptom of chronic rhinosinusitis is nasal 
congestion, and endoscopic sinus surgery (ESS) has been 
performed in such cases as a means of relieving congestion. 
The benefits of ESS in patients with chronic rhinosinusitis 
have been demonstrated in a number of studies. ESS produced 
significant improvements in symptoms including congestion 
and nasal obstruction,184,185 and in quality-of-life measures.186 International Journal of General Medicine 2010:3 85
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Patients who underwent ESS for chronic sinusitis also had 
significantly improved nasal endoscopy scores.186 Based 
on comparisons of pre- and postoperative rhinometry and 
rhinomanometry, ESS produces an increase in nasal cavity 
volumes and a decrease in nasal inspiratory resistance.185,187
Surgery remains an important treatment option for con-
gestion, particularly in subjects with inadequate response to 
prior therapeutic modalities or those with structural abnor-
malities. The potential benefits of surgical approaches should 
be weighed against the risk for complications.
Treatment of less common  
specific rhinopathies
In addition to the common rhinopathies of allergic rhinitis 
and acute and chronic sinusitis, there are a number of specific 
nasal conditions that are associated with symptoms of nasal 
congestion. Several of these are listed in the Table 1, along 
with recommendations for their treatment.
Summary
Congestion is a cardinal symptom of upper respiratory dis-
eases and is often a focus of treatment. In all cases, a stepwise 
approach is recommended for the management and treatment 
of congestion, consisting of (1) diagnosis of the cause(s), (2) 
patient education and monitoring, (3) avoidance of environ-
mental trigger factors where possible, (4) pharmacotherapy, 
and (5) allergen immunotherapy (only in patients with allergic 
rhinitis) or surgery for patients in whom the condition cannot 
be controlled with the previous measures.
A variety of pharmacologic therapies are available for 
the treatment of nasal congestion in various upper respira-
tory diseases, such as allergic rhinitis, nonallergic/vasomotor 
rhinitis, rhinosinusitis, nasal polyposis, and the common cold. 
The most extensively evaluated therapies for congestion 
include antihistamines, decongestants, leukotriene receptor 
antagonists, and intranasal corticosteroids. Intranasal steroids 
are currently the most effective medication available for the 
treatment of congestion associated with allergic rhinitis and 
have also demonstrated effective congestion relief in other 
upper respiratory diseases. It is important to note that while 
intranasal steroids have proven to be more effective than other 
classes of agents for the relief of congestion in controlled 
clinical trials, they do not reduce mean nasal congestion scores 
to normal levels, nor do they effectively reduce congestion 
in every patient. Thus, the efficacy of a particular therapeutic 
selection should be evaluated for each patient, with clinical 
trial results and comparison studies informing therapy con-
siderations and helping to establish expectations.
Immunotherapy has emerged as an effective option for 
those patients with allergic rhinitis in whom pharmacotherapy 
is insufficient, while surgery may be warranted in cases of 
severe refractory congestion or in patients with structural 
abnormalities. Treatment of less common rhinopathies should 
be tailored to the individual diagnosis and the needs of the 
particular patient.
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